|
1
|
Marques FK and Sabino AP: Myelodysplastic
neoplasms: An overview on diagnosis, risk-stratification, molecular
pathogenesis, and treatment. Biomed Pharmacother.
156(113905)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ogawa S: Genetics of MDS. Blood.
133:1049–1059. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nakajima H: Molecular pathogenesis and
treatment of myelodysplastic syndromes. Intern Med. 60:15–23.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shallis RM, Ahmad R and Zeidan AM: The
genetic and molecular pathogenesis of myelodysplastic syndromes.
Eur J Haematol. 101:260–271. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Haferlach T: The molecular pathology of
myelodysplastic syndrome. Pathobiology. 86:24–29. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Valent P, Orazi A, Steensma DP, Ebert BL,
Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers
TM, Wells DA, et al: Proposed minimal diagnostic criteria for
myelodysplastic syndromes (MDS) and potential pre-MDS conditions.
Oncotarget. 8:73483–73500. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Garcia-Manero G: Myelodysplastic
syndromes: 2023 update on diagnosis, risk-stratification, and
management. Am J Hematol. 98:1307–1325. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bejar R: Clinical and genetic predictors
of prognosis in myelodysplastic syndromes. Haematologica.
99:956–964. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Martín I, Such E, Navarro B, Villamón E,
Vicente A, Mora E, Pedrola L, Ibáñez M, López-Pavía M, Tormo M, et
al: Prognostic impact of gene mutations in myelodysplastic
syndromes with ring sideroblasts. Blood Cancer J.
7(630)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Maurya N, Mohanty P, Dhangar S, Panchal P,
Jijina F, Mathan SLP, Shanmukhaiah C, Madkaikar M and Vundinti BR:
Comprehensive analysis of genetic factors predicting overall
survival in Myelodysplastic syndromes. Sci Rep.
12(5925)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ma J, Gu Y, Wei Y, Wang X, Wang P, Song C
and Ge Z: Evaluation of new IPSS-Molecular model and comparison of
different prognostic systems in patients with myelodysplastic
syndrome. Blood Sci. 5:187–195. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee WH, Tsai MT, Tsai CH, Tien FM, Lo MY,
Tseng MH, Kuo YY, Liu MC, Yang YT, Chen JC, et al: Validation of
the molecular international prognostic scoring system in patients
with myelodysplastic syndromes defined by international consensus
classification. Blood Cancer J. 13(120)2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gu S, Xia J, Tian Y, Zi J and Ge Z: A
novel scoring system integrating molecular abnormalities with
IPSS-R can improve the risk stratification in patients with MDS.
BMC Cancer. 21(134)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Khoury JD, Solary E, Abla O, Akkari Y,
Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et
al: The 5th edition of the World Health Organization Classification
of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic
Neoplasms. Leukemia. 36:1703–1719. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bernard E, Tuechler H, Greenberg PL,
Hasserjian RP, Arango Ossa JE, Nannya Y, Devlin SM, Creignou M,
Pinel P, Monnier L, et al: Molecular international prognostic
scoring system for myelodysplastic syndromes. NEJM Evid.
1(EVIDoa2200008)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
von Elm E, Altman DG, Egger M, Pocock SJ,
Gøtzsche PC and Vandenbroucke JP: STROBE Initiative. The
strengthening the reporting of observational studies in
epidemiology (STROBE) statement: Guidelines for reporting
observational studies. J Clin Epidemiol. 61:344–349.
2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cook MR, Karp JE and Lai C: The spectrum
of genetic mutations in myelodysplastic syndrome: Should we update
prognostication? EJHaem. 3:301–313. 2021.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Bejar R, Stevenson K, Abdel-Wahab O,
Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine
RL, Neuberg D and Ebert BL: Clinical effect of point mutations in
myelodysplastic syndromes. N Engl J Med. 364:2496–2506.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Haferlach T, Nagata Y, Grossmann V, Okuno
Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T,
et al: Landscape of genetic lesions in 944 patients with
myelodysplastic syndromes. Leukemia. 28:241–247. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhao P, Qin J, Liu W, Quan R, Xiao H, Liu
C, Li L, Lv Y, Zhu Q, Wang H, et al: Genetic alterations in 47
patients with a novel myelodysplastic syndrome diagnosis at a
single center. Oncol Lett. 18:5077–5084. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yu J, Li Y, Li T, Li Y, Xing H, Sun H, Sun
L, Wan D, Liu Y, Xie X and Jiang Z: Gene mutational analysis by NGS
and its clinical significance in patients with myelodysplastic
syndrome and acute myeloid leukemia. Exp Hematol Oncol.
9(2)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liu M, Wang F, Zhang Y, Chen X, Cao P, Nie
D, Fang J, Wang M, Liu M and Liu H: Gene mutation spectrum of
patients with myelodysplastic syndrome and progression to acute
myeloid leukemia. Int J Hematol Oncol. 10(IJH34)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Saygin C and Godley LA: Genetics of
myelodysplastic syndromes. Cancers (Basel). 13(3380)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kennedy JA and Ebert BL: Clinical
implications of genetic mutations in myelodysplastic syndrome. J
Clin Oncol. 35:968–974. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Polprasert C, Kongkiatkamon S, Niparuck P,
Rattanathammethee T, Wudhikarn K, Chuncharunee S, Kobbuaklee S,
Suksusut A, Lanamtieng T, Lawasut P, et al: Genetic mutations
associated with blood count abnormalities in myeloid neoplasms.
Hematology. 27:765–771. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Stockton SS, Malhotra V, Lu X, Thangavelu
M, Albitar M and Cogle CR: Gene mutations in MDS associating with
peripheral blood count abnormalities. Blood. 126(1685)2015.
|
